Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Taniguchi

Showing results (181-190 of 191) with videos related to

Pageof 20
Sort By:
Medical Oncology (Northwood, London, England)|November 23, 2019
Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancerTaizo Uchimoto, Kazumasa Komura, Yuya Fujiwara, et al.
Cancers|February 12, 2021
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate CancerTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Cancers|July 24, 2021
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in JapanTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Cancer Science|September 27, 2023
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumabKazumasa Komura, Satoshi Tokushige, Mitsuaki Ishida, et al.
Annals of Surgical Oncology|September 17, 2025
ASO Author Reflections: Predictors of Immune Checkpoint Inhibitor Response in ER+/HER2- Breast Cancer: A New Role for ESR1?Jun Arima, Kohei Chida, Rongrong Wu, et al.
Japanese Journal of Clinical Oncology|January 9, 2021
Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement studyHitoshi Tsuda, Masayuki Yoshida, Futoshi Akiyama, et al.
Journal for Immunotherapy of Cancer|January 18, 2022
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancerKazuki Nishimura, Kyosuke Nishio, Kensuke Hirosuna, et al.
Faraday Discussions|October 2, 2023
Interdisciplinary electrosynthesis: general discussionLutz Ackermann, Mickaël Avanthay, Belen Batanero, et al.
The Journal of Clinical Investigation|June 5, 2018
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5DKazumasa Komura, Yuki Yoshikawa, Teppei Shimamura, et al.
Molecular Cancer|November 19, 2023
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder CancerKazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, et al.
Pageof 20

Showing results (181-190 of 191) with videos related to

Sort By:
Pageof 20
Medical Oncology (Northwood, London, England)|November 23, 2019
Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancerTaizo Uchimoto, Kazumasa Komura, Yuya Fujiwara, et al.
Cancers|February 12, 2021
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate CancerTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Cancers|July 24, 2021
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in JapanTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Cancer Science|September 27, 2023
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumabKazumasa Komura, Satoshi Tokushige, Mitsuaki Ishida, et al.
Annals of Surgical Oncology|September 17, 2025
ASO Author Reflections: Predictors of Immune Checkpoint Inhibitor Response in ER+/HER2- Breast Cancer: A New Role for ESR1?Jun Arima, Kohei Chida, Rongrong Wu, et al.
Japanese Journal of Clinical Oncology|January 9, 2021
Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement studyHitoshi Tsuda, Masayuki Yoshida, Futoshi Akiyama, et al.
Journal for Immunotherapy of Cancer|January 18, 2022
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancerKazuki Nishimura, Kyosuke Nishio, Kensuke Hirosuna, et al.
Faraday Discussions|October 2, 2023
Interdisciplinary electrosynthesis: general discussionLutz Ackermann, Mickaël Avanthay, Belen Batanero, et al.
The Journal of Clinical Investigation|June 5, 2018
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5DKazumasa Komura, Yuki Yoshikawa, Teppei Shimamura, et al.
Molecular Cancer|November 19, 2023
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder CancerKazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, et al.
Pageof 20